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Abstract: High intrauterine cortisol exposure can inhibit fetal growth and have programming
effects for the child’s subsequent stress reactivity. Placental 11beta-hydroxysteroid dehydrogenase
(11β-HSD2) limits the amount of maternal cortisol transferred to the fetus. However, the relationship
between maternal psychopathology and 11β-HSD2 remains poorly defined. This study examined
the effect of maternal depressive disorder, antidepressant use and symptoms of depression and
anxiety in pregnancy on placental 11β-HSD2 gene (HSD11B2) expression. Drawing on data
from the Mercy Pregnancy and Emotional Wellbeing Study, placental HSD11B2 expression was
compared among 33 pregnant women, who were selected based on membership of three groups;
depressed (untreated), taking antidepressants and controls. Furthermore, associations between
placental HSD11B2 and scores on the State-Trait Anxiety Inventory (STAI) and Edinburgh Postnatal
Depression Scale (EPDS) during 12–18 and 28–34 weeks gestation were examined. Findings revealed
negative correlations between HSD11B2 and both the EPDS and STAI (r = ´0.11 to ´0.28), with
associations being particularly prominent during late gestation. Depressed and antidepressant
exposed groups also displayed markedly lower placental HSD11B2 expression levels than controls.
These findings suggest that maternal depression and anxiety may impact on fetal programming
by down-regulating HSD11B2, and antidepressant treatment alone is unlikely to protect against
this effect.
Keywords: 11-beta hydroxysteroid dehydrogenase type 2; placenta 11β-HSD2; HSD11B2; prenatal
depression; prenatal anxiety; cortisol; fetal programming
1. Introduction
Maternal depression and anxiety during pregnancy has been associated with adverse
neurodevelopmental outcomes for the offspring, such as attention deficit hyperactivity disorder [1]
schizophrenia [2], poor cognitive or emotional developmental [3] and autism [4], although the
mechanisms involved remain elusive. Some recent studies [5–8] examining the role of maternal-fetal
cortisol regulation over pregnancy have found that depression and anxiety during pregnancy
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increases maternal cortisol concentrations, with the intrauterine environment reflecting this
elevation [9]. The fetus is typically exposed to 10%–20% of maternal cortisol [10] and high levels
in utero may hinder neonatal development [11,12]. For example, Bergman et al. (2010) [11] found
that fetal cortisol exposure (indexed by amniotic fluid levels) negatively predicted cognitive ability in
17 month old infants. However, research investigating the relationship between cortisol and maternal
distress is inconsistent [13–15] and therefore the suggestion that maternal depression or anxiety
enhances the possibility of negative infant outcomes by increasing maternal cortisol levels has not
been widely accepted.
11beta-Hydroxysteroid Dehydrogenase type 2 (11β-HSD2), an enzyme highly expressed in
aldosterone-selective tissues (distal nephron, colon) and the placenta [16,17], usually limits the
amount of maternal cortisol transferred to the fetus by converting cortisol into an inactive metabolite,
cortisone [16]. Expression levels of 11β-HSD2 (encoded by the gene, HSD11B2) rise in parallel
with increasing cortisol levels across pregnancy, protecting the fetus from excess cortisol exposure
in utero [18,19]. Thus, another theory suggests that 11β-HSD2 gene expression is downregulated by
maternal depression or anxiety, resulting in more cortisol being transferred from the mother to the
fetus, subsequently contributing to negative infant outcomes.
In support of HSD11B2 expression mediating the relationship between maternal distress and
infant outcomes, a recent study [20] selectively bred Wistar rats for high anxiety-related behaviour
or low anxiety-related behaviour and exposed both groups to identical stressors. Those bred for
high anxiety had significantly lower placental HSD11B2 expression levels than the low anxiety
group. Additional animal studies on rats also indicate that exposure to chronic stress downregulates
HSD11B2 [21–24] but report that acute maternal stress upregulates its expression [22,25].
Furthermore, these studies [20,21,23] suggest that the association between maternal anxiety or stress
and placental HSD11B2 is specific to maternal distress during late pregnancy.
Although animal research suggests that HSD11B2 is affected by maternal stress or anxiety in
late gestation and is differentially influenced by chronic versus acute symptoms, the applicability of
these findings to humans is currently unknown and should be considered in the context of altering
levels of maternal distress across pregnancy. For example, there is significant variability in anxiety
and depressive symptoms during the perinatal period in humans; some studies report maternal
symptoms to be relatively stable during pregnancy [26,27], others identify increasing symptom
rates across pregnancy [28] or a u-shaped pattern, where symptoms peak during the first and third
trimesters [29,30]. To our knowledge, no study has yet investigated the effects of changing depressive
and anxiety symptoms across pregnancy on placental HSD11B2 expression. However, since animal
research [21,23] suggests that placental HSD11B2 may be influenced by gestation and the chronicity
of maternal distress, it is possible that the episodic nature of prenatal depression and anxiety also has
an influence on the expression of placental HSD11B2.
In human research to date, three studies have investigated the influence of maternal distress on
placental HSD11B2 expression levels, with contrasting findings [31–33]. Specifically, O’Donnell et al.
(2012) [32] and Ponder et al. (2011) [31] investigated the effect of both anxiety and depression
while Reynolds et al. (2015) [33] examined depression alone. In terms of anxiety, O’Donnell et al.
(2012) [32] found that maternal anxiety in late pregnancy significantly downregulated HSD11B2 (by
approximately 30%) [32]. In contrast, Ponder et al. (2011) [31] compared 11β-HSD2 gene expression in
women grouped into three categories; those exposed to selective serotonin reuptake inhibitors (SSRI),
women with untreated depressive or anxiety symptoms, and a control group. They reported greater
expression in the SSRI and depressed/anxious groups in comparison to controls, but this difference
did not reach significance. When considering depression alone, O’Donnell et al. (2012) [32] found that
maternal depression displayed a negative but non-significant association with HSD11B2 expression
while Reynolds et al. (2015) [33] reported a positive non-significant association between HSD11B2
expression and depressive symptoms across all trimesters of pregnancy.
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One possible reason for the variations in findings can be attributed to methodological differences.
O’Donnell and Reynolds [32,33] used self-report measures to identify maternal depression and
anxiety whereas Ponder et al. (2011) [31] used retrospective medical records, where a diagnosis of
depression or anxiety was elicited by a medical provider or endorsed by the patient at any time
during pregnancy. In addition, timing of assessment and placental collection varied across studies.
Ponder et al. (2011) [31] retrieved antenatal health records early in pregnancy, while Reynolds et al.
(2015) [33] measured depression across repeated intervals from 12–14 weeks gestation to term.
In contrast, O’Donnell et al. (2012) [32] administered self-report questionnaires one day prior to
the participant’s elective caesarean, when participant responses might have been influenced by
their pending surgery and birth. Furthermore, the time taken to process placental tissue differed
between studies; O’Donnell et al. (2012) [32], Reynolds et al. (2015) [33] and Ponder et al. (2011) [31]
processed samples within 1 h, 90 min and 3 h after delivery, respectively. Collection of the placenta
and processing time can effect RNA integrity, with Jobarteh et al. (2014) [34] recommending that
samples be processed within 90 min of delivery for gene expression studies. Moreover, potential
important confounding variables were not consistently controlled for across studies. For instance,
smoking and obesity increase norepinephrine in the body [34–36], which suppresses HSD11B2
expression levels [34,35,37]. Likewise, preeclampsia has also been associated with lower levels of
HSD11B2 [38]. O’Donnell et al. (2012) [32] did not control for obesity and none of the studies controlled
for preeclampsia, with Reynolds et al. (2015) [33] specifically including participants at high risk of this
condition. Thus, these factors may lower gene expression of 11β-HSD2 in some participants and need
to be considered as possible confounders.
The current study aimed to investigate the effect of maternal depressive disorders, symptoms of
maternal anxiety and depression across pregnancy on HSD11B2 expression levels. In doing so, the
study also intended to determine whether maternal anxiety or depression symptoms have different
effects on HSD11B2 expression. Since some animal studies have found downregulation of HSD11B2
specifically during late gestation [21,23], another aim of our research was to investigate whether
depressive symptoms and anxiety measured in the first compared to the third trimester of pregnancy
have a differential impact on placental HSD11B2 expression. Furthermore, the effect of changing
anxiety and depressive symptoms across pregnancy on placental HSD11B2 expression was examined
and given that only one study to date (Ponder et al. 2011 [31]) has investigated the association between
antidepressants and HSD11B2 [39], the impact of antidepressant exposure on placental HSD11B2 was
considered. Lastly, the relationship between HSD11B2 expression and participant characteristics such
as Body Mass Index (BMI), smoking and alcohol consumption has been investigated in this study.
Based on the literature, we hypothesize that: (1) anxiety and depressive symptoms will be
negatively associated with HSD11B2 expression; (2) the effect of anxiety and depressive symptoms
on HSD11B2 will be greater during the third trimester than the first; (3) changes in depression and
anxiety symptoms across pregnancy will be inversely related to HSD11B2 expression levels; (4) in
accordance with Ponder et al. (2011)’s study [31], anxiety will have a significantly greater effect on
HSD11B2 than depression; (5) smoking, alcohol consumption and BMI will be negatively associated
with HSD11B2 expression levels; and (6) HSD11B2 expression will be lower in women with a major
depressive episode and those exposed to antidepressants than controls [39].
2. Results
2.1. Preliminary Analyses
In terms of changes in anxiety or depressive symptoms across pregnancy, a paired-samples t-test
revealed that participant STAI-T (trait anxiety) scores did not significantly or notably differ between
Trimester 1 and 3 (t (32) = 1.14, p = 0.17), remaining relatively stable across gestation. However, a
marked positive (although non-significant) improvement in EPDS scores (t (32) = 1.85, p = 0.07) and a
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significant improvement in STAI-S (state anxiety) scores between trimesters was found (t (32) = 2.41,
p = 0. 02).
Correspondence between the Structured Clinical Interview for DSM-IV Disorders (SCID) and the
Edinburgh Postnatal Depression Scale (EPDS)
Out of the nine participants that received a diagnosis of current depression based on the SCID
(including one participant that was taking antidepressants), six had an EPDS score of 13 or greater
(the validated cut-off score to detect probable cases of major depression [40,41]) in the first trimester
and three had a score of 13 or greater in the third trimester. The SCID was administered in Trimester 1
and therefore the greater consistency observed between SCID diagnoses and Trimester 1 EPDS scores
(in comparison to Trimester 3 scores) was expected.
2.2. Confirmatory Analyses
The first four hypotheses were tested using regression analyses including all participants and
the last hypothesis was tested by comparing HSD11B2 expression levels between participant groups;
depressed (untreated), taking antidepressants and controls (see Experimental Section for details).
All statistical analyses remained robust to the exclusion of an outlier in the Trimester 3 EPDS
scores and two outliers in the Trimester 3 STAI-S scores.
2.2.1. Hypotheses 1 and 2: The Effects of Self-Reported Maternal Anxiety and Depressive Symptoms
on 11β-HSD2 Gene Expression
As presented in Table 1, Pearson correlations showed negative relationships between HSD11B2
expression and measures of anxiety (STAI-T, STAI-S) in the first and third trimesters of pregnancy.
However, although in the predicted direction, these associations did not reach significant alpha levels
given the small sample size. These bivariate correlations further revealed a greater effect in the third
trimester of pregnancy, where state and trait anxiety in combination accounted for 14% of variance in
HSD11B2 expression levels (R2 = 0.08 and 0.06 respectively), in comparison to 7% (R2 = 0.01 and 0.06
respectively) in Trimester 1 (see Table 1).
Table 1. Pearson Correlations between 11β-HSD2 Gene Expression, Maternal Mood and Participant
Characteristics during Trimester 1 and 3.
Participant Variables Relative 11β-HSD2/L9 Expression (n = 33)
T1 T3 Differences between T1 and T3
STAI (Trait Anxiety) ´0.24 (p = 0.22) ´0.25 (p = 0.12) 0.04 (p = 0.82)
STAI (State Anxiety) ´0.10 (p = 0.64) ´0.28 (p = 0.14) ´0.16 (p = 0.38)
EPDS ´0.11(p = 0.53) ´0.27 (p = 0.15) ´0.22 (p = 0.21)
Smoking (nicotine consumption) ´0.09 (p = 0.60) ´0.07 (p = 0.71) -
Alcohol consumption ´0.17 (p = 0.34) ´0.20 (p = 0.26) -
BMI 0.08 (p = 0.67) - -
STAI = State-Trait Anxiety Inventory; EPDS = Edinburgh Postnatal Depression Scale; T1 = Trimester 1;
T3 = Trimester 3; BMI = Body Mass Index.
Pearson correlations also revealed a negative relationship between depressive symptoms (as
measured by the EPDS) and HSD11B2. Similar to anxiety, the effect was greater in the third trimester
than the first, with 7% of the variation in HSD11B2 being explained by Trimester 3 EPDS scores (in
comparison to 1.25% during the first trimester).
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2.2.2. Hypothesis 3: Relationship between HSD11B2 and Changes in Depressive and Anxiety
Symptoms across Pregnancy
Correlations between HSD11B2 expression and changes in scores on the EPDS and STAI-S (state
anxiety) between the first and third trimester suggested negative relationships (see Table 1), while the
correlation between HSD11B2 and changes in STAI-T (trait anxiety) remained positive (see Figure 1).Int. J. Mol. Sci. 2015, 16, page–page 
5 
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Figure 1. Placental HSD11B2 expression and Trimester 3 (A) EPDS scores (M = 6.22, SD = 4.50);  
(B) STAI-T scores (M = 36.48, SD = 10.38); and (C) STAI-S scores (M = 34.35, SD = 10.30). 
2.2.3. Hypothesis 4: Comparison between Anxiety and Depression; Strength of their Association 
with HSD11B2 
Fischer’s R-Z transformations were used to test the strength of association between maternal 
trait anxiety and placental HSD11B2, relative to other measures of maternal mood. In relation to the 
strength of their association with HSD11B2, results indicated that maternal trait and state anxiety in 
both Trimester 1 and 3 did not significantly differ from each other. Likewise, the correlations between 
maternal depression and HSD11B2 expression were are not significantly different from associations 
between HSD11B2 expression and state or trait anxiety in either trimester. 
2.2.4. Hypothesis 5: The Influence of Alcohol Consumption, Smoking and Body Mass Index  
on HSD11B2 
Pearson correlations revealed a negative effect of alcohol consumption and smoking on 
HSD11B2 expression levels, while a positive correlation was found between BMI and HSD11B2 (see 
Table 1). An Analysis of Covariance (ANCOVA) indicated that BMI in Trimester 1 of pregnancy 
contributed to 0.2% of the relationship between HSD11B2 and group status, while alcohol in 
Trimester 3 accounted for 5% of this relationship. Meanwhile, smoking in Trimester 3 of pregnancy 
showed a negligible (ηp2 = 0.002, p = 0.53) effect on HSD11B2. 
  
Figure 1. Placental HSD11B2 expression and Trimester 3 (A) EPDS scores (M = 6.22, SD = 4.50);
(B) STAI-T scores (M = 36.48, SD = 10.38); and (C) STAI-S scores (M = 34.35, SD = 10.30).
2.2.3. Hypothesis 4: Comparison between Anxiety and Depression; Strength of their Association
with HSD11B2
Fischer’s R-Z transformations we used t test the strength of association b tween maternal
trait anxiety and placental HSD11B2, relative to other measures of maternal mood. In relation to the
strength of their association with HSD11B2, results indicated that maternal trait and state anxiety in
both Trimester 1 and 3 did not significantly differ from each other. Likewise, the correlations between
maternal depression and HSD11B2 expression were are not significantly different from associations
between HSD11B2 expression and state or trait anxiety in either trimester.
2.2.4. Hypothesis 5: The Influence of Alcohol Consumption, Smoking and Body Mass Index
on HSD11B2
Pearson correlations revealed a negative effect of alcohol consumption and smoking on HSD11B2
expression levels, while a positive correlation was found between BMI and HSD11B2 (see Table 1).
An Analysis of Covariance (ANCOVA) indicated that BMI in Trimester 1 of pregnancy contributed to
27486
Int. J. Mol. Sci. 2015, 16, 27482–27496
0.2% of the relationship between HSD11B2 and group status, while alcohol in Trimester 3 accounted
for 5% of this relationship. Meanwhile, smoking in Trimester 3 of pregnancy showed a negligible
(ηp2 = 0.002, p = 0.53) effect on HSD11B2.
2.2.5. Hypothesis 6: Comparison of HSD11B2 Expression Levels between Groups
An ANCOVA controlling for BMI, smoking and alcohol consumption revealed that group
status (antidepressant exposure, untreated depression and controls) accounted for 5.9% of HSD11B2
expression (F (2, 32) = 0.84, p = 0.44, n = 33) instead of 7.1% (the computed effect size without
consideration of covariates). The ANCOVA also revealed that participants with untreated depression
and antidepressant exposure had markedly lower HSD11B2 concentrations than controls (refer to
Figure 2). Excluding the participant with limited antidepressant exposure in this analysis produced
almost identical results (F (2, 31) = 0.85, p = 0.44, n = 32), indicating that the findings are robust to this
sensitivity analysis.
Int. J. Mol. Sci. 2015, 16, page–page 
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Figure 2. Comparisons of placental HSD11B2 expression levels between the control, depressed 
(untreated) and antidepressant exposed groups. Histogram shows mean values +/− standard error of 
the mean. 
3. Discussion 
This pilot study was broadly in line with predictions and produced a number of important and 
novel findings. Although none of our results were statistically significant due to a small sample size, 
the effect sizes and direction of associations are of interest and indicate meaningful findings. First, 
we found negative associations between HSD11B2 expression and self-reported maternal anxiety and 
depression. Likewise, changes in self-reported maternal state anxiety and depressive symptoms from 
Trimester 1 to 3 were negatively related to HSD11B2, where improvements in maternal mental health 
(lower EPDS and STAI scores) led to higher placental HSD11B2 expression levels. As an exception, 
the relationship between trait anxiety and HSD11B2 did not differ considerably between trimesters; 
however this is consistent with the nature of trait anxiety, which is relatively stable across time. 11β-HSD2 
limits the amount of cortisol that is transferred from the mother to the fetus [16] and therefore, these 
results suggest that maternal anxiety and depressive symptoms may increase fetal cortisol exposure. 
Furthermore, maternal anxiety and depression measured in late gestation displayed stronger 
associations with placental HSD11B2 expression levels than maternal depression and anxiety in early 
pregnancy (12–18 weeks). This is consistent with previous animal research [21,23] and the human 
study of O’Donnell et al. (2012) [32], where maternal anxiety was measured one day before term and 
exhibited a significant positive association with the downregulation of HSD11B2. These findings are 
also noteworthy because maternal cortisol levels are usually at their peak during the third trimester 
of pregnancy [42]. Although it might be suggested that the association between HSD11B2 and 
maternal distress is stronger in the third trimester due to worsening of anxiety and depressive 
symptoms across pregnancy, our results indicate a significant improvement in state anxiety and a 
notable improvement (although non-significant) in depressive symptoms, from Trimester 1 to 3 [43]. 
Figure 2. Comparisons of placental HSD11B2 expression levels between the control, depressed
(untreated) and antidepressant exposed groups. Histogram shows mean values +/´ standard error
of the mean.
3. Discussion
This pilot study was broadly in lin with p dic ons and produce a number of i portant and
novel findings. Although none of our results were statistically significant due to a small sample size,
the effect sizes and direction of associations are of interest and indicate meaningful findings. First,
we found negative associations between HSD11B2 expression and self-reported maternal anxiety and
depression. Likewise, changes in self-reported maternal state anxiety and depressive symptoms from
Trimester 1 to 3 were negatively related to HSD11B2, where improvements in maternal mental health
(lower EPDS and STAI scores) led to higher placental HSD11B2 expression levels. As an exception,
the relationship between trait anxiety a d HSD11B2 did not differ considerably between trimesters;
however this is consistent with the nature of trait anxiety, which is relatively stabl across time.
11β-HSD2 limits the amount of cortisol that i transferred from the mother to the fetus [16] and
therefore, these results suggest that maternal anxiety and depressive symptoms may increase fetal
cortisol exposure.
Furthermore, maternal anxiety and depression measured in late gestation displayed stronger
associations with placental HSD11B2 expression levels than maternal depression and anxiety in
early pregnancy (12–18 weeks). This is consistent with previous animal research [21,23] and the
human study of O’Donnell et al. (2012) [32], where maternal anxiety was measured one day before
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term and exhibited a significant positive association with the downregulation of HSD11B2. These
findings are also noteworthy because maternal cortisol levels are usually at their peak during the third
trimester of pregnancy [42]. Although it might be suggested that the association between HSD11B2
and maternal distress is stronger in the third trimester due to worsening of anxiety and depressive
symptoms across pregnancy, our results indicate a significant improvement in state anxiety and a
notable improvement (although non-significant) in depressive symptoms, from Trimester 1 to 3 [43].
Thus, based on our findings and O’Donnell’s research [32], it is suggested that elevated maternal
cortisol accompanied with lowered HSD11B2 expression levels during late gestation may be sufficient
to adversely affect fetal development, reflecting a possible mechanism between maternal distress and
fetal programming.
The results further indicate that women with untreated major depression and those
using antidepressants have markedly lower placental HSD11B2 expression levels than controls.
However, a notable difference in placental HSD11B2 expression was not evident between women
taking antidepressant medication and those with untreated depression, which may suggest that
antidepressant treatment alone is not effective in reversing the effects of maternal depression and
anxiety on HSD11B2 expression. These findings are consistent with our hypotheses and the findings
of O’Donnell et al. (2012) [32], which found a 30% reduction in placental HSD11B2 expression in
anxious pregnant women and a negative (although non-significant) association between maternal
depression and HSD11B2. In contrast to O’Donnell et al. (2012) [32] however, maternal anxiety did
not have a greater effect on HSD11B2 than depression in our study. Furthermore, our results disagree
with Reynolds et al. (2015) [33] and Ponder et al. (2011) [31], where antidepressant exposure and
self-reported maternal depression were found to upregulate placental HSD11B2 expression levels.
The variation in findings can be attributed to a range of limitations and methodological
differences between studies related to outcome measures, time of processing samples and the
gestational period at which anxiety and depression were assessed. Furthermore, findings may be
influenced by whether chronic or acute depressive or anxiety symptoms were measured. Acute
stress in pregnant rats has been found to increase placental 11β-HSD2 enzyme activity [22,24]
and betamethasone treatment (which rapidly increases maternal cortisol levels) within 72 h of
birth has also been reported to increase 11β-HSD2 enzymatic activity in postpartum women [44].
In contrast, animal research has indicated that chronic stress lowers HSD11B2 expression in the
placenta [20–23,25]. Thus, it is possible that acute depression or anxiety upregulates HSD11B2 while
chronic depression or anxiety has the opposite effect. This important point of difference requires
further investigation.
It can be argued that the negative association between maternal distress and HSD11B2
expression found in this study supports the premise that acute stress upregulates while chronic
stress downregulates HSD211B2, since major depressive disorders were measured (using the SCID)
rather than situational distress and most participants that screened positive for antenatal depression
have a history of depression prior to pregnancy. Furthermore, studies (Ponder et al. 2011 [31] and
Reynolds et al. 2015 [33]) reporting a positive relationship between HSD11B2 and maternal mood
used medical records and the CES-D as a basis for diagnosis, arguably measuring less severe or
chronic symptomology than the SCID. Although our findings also report a negative relationship
between HSD11B2 and self-reported maternal anxiety and depression (using the EPDS and STAI),
a study [45] comparing the EPDS and CES-D found that the EPDS is a better predictor of major
depression and attuned to greater symptom severity than the CES-D. In addition, majority (67%) of
participants diagnosed with a major depressive episode on the SCID obtained an EPDS score of 13
or greater in our study and Reynolds et al. (2015) [33] only identified 12.5%–16.3% of participants as
exhibiting high CES-D scores. Thus, it is possible that human research also lends support to the
idea that downregulation of HSD11B2 expression is related to chronic depression or anxiety and
upregulation is associated with acute distress.
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Theoretically, it is suggested that HSD11B2 expression levels increase in women with acute stress
to levels greater than normal (as seen in the findings of Reynolds and Ponder), since the placenta
aims to protect the fetus from excess glucocorticoids produced by mothers during this period [21].
In contrast, chronic stress may be characterized by hypocortisolemia (insufficient production of
cortisol) [46] or epigenetic changes in the placenta, leading to the downregulation of HSD11B2.
Although the exact mechanism between maternal distress and downregulation of HSD11B2 is
unknown [21], elevations in proinflammatory cytokines [47,48], stimulation of the sympathoadrenal
system [49] and DNA methylation [21] have been implicated. However to date, no human study
has differentiated between the effects of acute, chronic, mild or severe depression or anxiety on
HSD11B2 expression, and greater research investigating the effect of distress severity and chronicity
on HSD11B2 is needed to test the suggested hypotheses.
3.1. The Influence of Smoking, BMI and Alcohol Consumption
The current study also explored the effect of smoking, BMI and alcohol consumption on
HSD11B2. The results indicated a negative relationship between smoking and alcohol consumption,
which is consistent with literature on the influence of norepinephrine (in nicotine) on HSD11B2.
However, there is insufficient research examining the relationship between alcohol and HSD11B2,
with the current study providing some direction. In contrast, a positive but non-significant association
between the first trimester HSD11B2 expression levels and participant BMI was found. This
is inconsistent with the hypothesis that BMI increases norepinephrine which in turn, lowers
HSD11B2 levels. However, these results are not surprising since a direct effect of obesity on
HSD11B2 is unknown and a range of factors may influence the obesity-norepinephrine- HSD11B2
interaction sequence.
3.2. Limitations and Strengths
The study (being a pilot study) has limited its sample size and subsequently, statistical power.
In addition, although six out of nine participants with a SCID diagnosis of depression scored 13 or
greater on the EPDS in Trimester 1, three participants in the depressed group did not, which suggests
some inconsistency in the screening of depressive symptoms in our study. Furthermore, participant
BMI was measured between 12–18 weeks gestation (which is not an accurate representation of a
woman’s BMI) and similar to all other studies, some suppressants of HSD11B2 expression such as
liquorice and carbenoxolone [50] were not controlled for. However, participants with preeclampsia
were excluded and the three groups formed (antidepressant exposed, untreated depressed and
controls) were matched on BMI and gestation. Another strength of this study is that associations
between HSD11B2 and changes in maternal distress across pregnancy were examined and the effect
of antidepressant exposure on HSD11B2, which has only ever been investigated by one other study
(Ponder et al. 2011 [31]), was considered. Furthermore, depression was measured by both self-report
measures and the SCID for DSM-IV, which allows for screening of both depressive symptoms and
major depression. In addition, placental samples were collected and processed within a half hour of
delivery, ensuring sampling quality. Although numerous procedural advantages can be identified in
the current research, due to the limited sample size, this study is primarily exploratory.
3.3. Lessons Learned in Current Study and Future Directions
Given the limitations of this study, it is suggested that future research;
1. Include an adequate sample size. A post hoc power analysis revealed that n = 193 participants are
required to conduct the analyses in this study and obtain statistical power of 0.80, with a medium
effect size of r = 0.20 and alpha significance level of 0.05. A further 58 participants (total n = 251)
are needed (30% of 193) if covariates (smoking, alcohol consumption and BMI) are included in the
analysis [51].
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2. Control for major suppressants of HSD11B2 such as liquorice and carbenoxolone.
3. Participant BMI values in this study may be inaccurate as they were based on measurements
during pregnancy. In future studies, the pre-pregnancy BMI of women should be obtained.
4. The current study used a structured interview to assess depression, but not anxiety. To enhance
our study design, a semi-structured or structured interview could have been used to measure
both constructs.
5. The current study had one participant that discontinued antidepressant medication during the
first 11 weeks of pregnancy. To cater for this, we conducted a sensitivity analysis excluding
this participant from the statistical analyses computed. However, ideally, all participants in the
antidepressant group should have consistent exposure to antidepressants across pregnancy to
avoid individual variability that can potentially bias results.
6. To optimally assess depression, anxiety and stress in pregnancy, the EPDS and STAI should be
administered during each trimester. Furthermore, a diagnostic assessment of DSM-V depression,
anxiety and stress related disorders should be conducted during the beginning and end of
pregnancy. Although there is currently no diagnostic measure designed specifically for pregnancy,
assessment tools such as the SCID have been widely used in psychiatric research studies [52]. The
diagnostic measure at the start of pregnancy should assess both current and lifetime mental health
disorders while the diagnostic measure at the end of pregnancy should assess onset and course
of disorders occurring during pregnancy as well as the continuity/discontinuity of pre-existing
disorders. It would also be important in this protocol to rule out other classes of mental disorder.
Furthermore, to expand on the preliminary work conducted in this study, the finding that
antidepressant treatment alone does not normalize HSD11B2 expression levels needs to be explored
further, as this can contribute to understanding the impact of maternal depression and anxiety on
placental 11β-HSD2 enzymatic activity.
4. Experimental Section
4.1. Participants
This research is part of a larger cohort study known as the Mercy Pregnancy and Emotional
Wellbeing Study (MPEWS). This study reports on a selection of 33 participants who were recruited
from the Mercy Hospital for Women (Melbourne, Australia) during their first trimester (between 12
and 18 weeks’ gestation). Women with gestational diabetes mellitus (GDM) or preeclampsia were
excluded. As part of the larger MPEWS study, written informed consent, weight, height and contact
details were obtained from all participants at the time of recruitment.
At the time of initial contact in the first trimester, a questionnaire was administered which
included the Edinburgh Postnatal Depression Scale (EPDS), the State-Trait Anxiety Inventory
(STAI) and questions about the participants smoking status, exposure to antidepressants and
alcohol consumption. Furthermore, participants were assessed for a major mood disorder using the
Structured Clinical Interview for DSM-4 Disorders (SCID) during their first trimester and those who
screened positive for mania, bipolar disorder or psychotic disorders were excluded from the study. A
second questionnaire incorporating the same information as the first questionnaire was provided to
participants via mail and completed between 28–34 weeks gestation.
Participants were categorized into one of three groups; those exposed to antidepressants,
participants with a major depressive disorder (without antidepressant exposure) and a control group
(women with neither depression nor exposure to antidepressants). Participants were diagnosed with
depression based on the SCID assessment and participant exposure to antidepressants was derived
from their first questionnaire responses. Based on this assessment, there were eight participants
with current major depression, eight exposed to antidepressants during their pregnancy, and 17
controls. One participant exposed to antidepressants was also diagnosed with current depression and
another two participants within the antidepressant exposed group were diagnosed with depression
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in partial remission. The selection of controls was based on the development of a propensity score
match technique so that controls were matched to the two clinical groups on gestational age at the
time of delivery and maternal BMI during the first trimester of pregnancy, with participant BMI
being calculated by using the following formula: weight (kg)/height2 (m2). Medications in the
antidepressant group included serotonergic antidepressants including selective serotonergic reuptake
inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs); five participants used
sertraline (50–150 mg daily), one used Duloxetine (120 mg daily), one used Venlafaxine (75 mg daily)
and one participant used Fluoxetine (10 mg daily).
4.2. Measures of Depression
4.2.1. The Structured Clinical Interview for DSM-IV Disorders
The Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I) is a well-known
semi-structured interview designed to detect DSM-IV axis I disorders [53]. It is divided into
separate modules corresponding to categories of diagnoses. Interviews were conducted by registered
psychologists or postgraduate trainee psychologists.
4.2.2. Edinburgh Postnatal Depression Scale
The Edinburgh Postnatal Depression Scale is a 10-item self-rating scale, developed by Cox et al.
(1987) [42] to detect perinatal depression. The reliability of the EPDS ranges from a Cronbach’s α
of 0.82 to 0.84 [54]. It has demonstrated high concurrent [54] and retest validity [55,56], and studies
report the measure as highly valid for detecting depression in a pregnant population [57,58]. A score
of 13 or above on this scale is used to identify women at risk of a depressive disorder [41].
4.3. Measures of Anxiety
State-Trait Anxiety Inventory
The State-Trait Anxiety Inventory is a commonly used measure of trait and state anxiety. It
includes 40 items in total, with 20 assessing trait anxiety (STAI-T) and the remaining 20 assessing state
anxiety (STAI-S). All items are rated on a four point Likert scale. Internal consistency coefficients for
the scale range from 0.89 to 0.91 [59] and considerable evidence attests to the construct and concurrent
validity of the scale [59].
4.4. 11β-HSD2 Gene (HSD11B2) Expression
Tissues were collected and processed within 30 min of delivery. Using a biopsy punch samples
were obtained at six different sites across the placenta for every participant, washed extensively with
phosphate-buffered saline, and immediately snap frozen in liquid nitrogen and stored at´80 ˝C until
extracted for RNA. Six different sites were chosen to obtain an accurate representation of the whole
placenta. Total RNA was extracted using TRIsure reagent according to manufacturer’s instructions
(Bioline; Alexandria, NSW, Australia), as previously described [60]. RNA concentration and purity
were measured using a NanoDrop ND1000 spectrophotometer (Thermo Fisher Scientific; Scoresby,
Australia). RNA was converted to cDNA using the SuperScript VILO cDNA synthesis kit (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions. Semi-quantitative Real Time
(RT)-PCR was carried out using the SYBR Green method (Bioline; Alexandria, Australia) with primer
annealing temperatures set to 60 ˝C. Placenta 11β-HSD2 gene expression analyses were assayed in
duplicate and normalized to the ribosomal protein L19, as detailed in O’Donnell et al. (2012) [32],
using the following primer sequences: 11β-HSD2 forward: 5’-GCTCATCACCGGGTGTGACT-31,
reverse: 5’-GGGCTGTTCAACTCCAATACG-31, L19 forward: 5’-CCAACTCCCGTCAGCAGATC-31,
reverse: 5’-CAAGGTGTTTTTCCGGCATC-31.
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4.5. Statistical Analysis
Statistical analyses were conducted using SPSS statistical software (version 22.0; SPSS Inc.,
Chicago, IL, USA). Missing data on one item of the wave 2 STAI-T for one participant was replaced
with equivalent item scores from their wave 1 STAI-T scale scores, since trait anxiety was relatively
stable across time in our study. Furthermore, the data for relative 11β-HSD2/L19 expression was not
normally distributed and all analyses included the bootstrap function (ˆ1000 samples) to cater for
this. Graphs were also constructed using log transformed data to address non-normality.
To test the hypothesis that HSD11B2 shares a negative relationship with maternal distress,
correlations between 11β-HSD2 mRNA levels and scores on anxiety and depression self-report
measures (EPDS and the STAI) were computed. These relationships are presented graphically (refer
to Figure 1). Likewise, to test the association between changes in maternal distress and HSD11B2,
differences in EPDS and STAI scores between Trimester 1 and 3 were calculated and correlations
between these differences and HSD11B2 expression were computed. Differences in participant EPDS
and STAI scores were obtained by subtracting first trimester scores from third trimester scores.
To determine whether anxiety or depression symptoms had a greater effect on HSD11B2
expression, Fischer’s R-Z transformations were calculated to compare correlation coefficients, using
the following formula:
Z “ 0.5loge rp1 ` rq{p1´ rqs (1)
If the Z value was greater or equal to 1.96 or less than or equal to ´1.96, the two correlations
being compared were considered significantly different at the p < 0.05 level of significance.
Pearson correlations between HSD11B2 and participant characteristics such as; BMI, smoking
and alcohol consumption were calculated to investigate these relationships.
In order to examine the hypothesis that placental 11β-HSD2 mRNA levels are lower in women
with a major depressive disorder and antidepressant exposed women, we used an Analysis of
Covariance (ANCOVA) with participant group (untreated participants with depression, participants
using antidepressants and controls) as the independent variable and 11β-HSD2 mRNA levels as the
outcome variable and then repeated the analysis controlling for nicotine use (in Trimester 3), alcohol
consumption (in Trimester 3), and BMI (in Trimester 1).
Furthermore, seven out of eight participants were exposed to antidepressants for majority
of their pregnancy while one participant used antidepressants only during the first 11 weeks
of pregnancy. Sensitivity analyses were performed, excluding the participant with limited
antidepressant exposure and participants with very high Trimester 3 EPDS and STAI-S scores
(outliers). Outliers were identified using boxplots and confirmed using the outlier labeling rule [61].
Lastly, for future research, a power analysis to determine an adequate sample size to test our
hypotheses was computed; using the software program G*Power 3.1 [62], an estimated sample size
was derived. To cater for covariates, an additional 30% of this estimated sample size was added to
form the total number of participants required.
5. Conclusions
In conclusion, the current study provides further evidence that placental 11β-HSD2 gene
expression is sensitive to both maternal antenatal anxiety and depression, particularly during the
third trimester of pregnancy. It is then hypothesized that the influence of maternal anxiety and
depression on 11β-HSD2 gene expression may act as a mediator between maternal distress and
cortisol exposure in utero, consistent with a mechanistic role in mediating the fetal programming
effects of maternal depression and anxiety on offspring outcomes. Furthermore, the study suggests
that antidepressant treatment and untreated depression have similar effects on HSD11B2. However,
given the limitations of all studies within this field (including the current study) and gaps within the
mechanistic understanding of maternal mood’s effect on HSD11B2 expression, further research needs
to be conducted.
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